A Study to Investigate the Efficacy and Safety of Dato-DXd with or without Osimertinib Compared with Platinum Based Doublet Chemotherapy in Participants with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Identifier:	D516KC00001
Sponsor:	AstraZeneca
Collaborator:	Daiichi Sankyo
NCTID::	NCT06417814
Start Date:	August 2024
Primary Completion Date:	September 2026
Study Completion Date:	February 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.